Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021

Zhou, Yue, Naci, Huseyin ORCID: 0000-0002-7192-5751, Chen, Dingyi, Bai, Lin, Shi, Luwen, Guan, Xiaodong and Wagner, Anita Katharina (2023) Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021. BMJ Global Health, 8 (9). ISSN 2059-7908

Text (Naci_overall-survival-benefits-of-cancer-drugs--published) - Published Version Available under License Creative Commons Attribution. Download (1MB)

• Author
• Scopus publication

Abstract

Introduction We examined overall survival (OS) benefits for targeted cancer drugs recommended for List of Essential Medicines (EMLs) since 2015. We assessed consistency of decisions in 2019 and 2021 with more specific criteria: OS benefit >4 months and high scores on European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). Methods We identified applications for cancer drug in WHO EMLs from 2015 to 2021. We extracted evidence of OS benefit documented in WHO Technical Report Series (TRS) and compared it to evidence from pivotal trial(s) documented in Food and Drug Administration-approved labels. We retrieved published ESMO-MCBS scores. We summarised availability and magnitude of OS benefit and ESMO-MCBS scores and assessed consistency of inclusion decisions against WHO criteria. Results 22/54 targeted cancer drug indications were recommended. Among them, 68.2% and 31.8% had OS benefit evidence documented in WHO-TRS and pivotal trials, respectively. Among those not recommended, 59.4% and 56.3% had OS benefit evidence documented in WHO-TRS and pivotal trials, respectively. Of 11 cancer drug indications recommended in 2019 and 2021, 54.5% and 9.1% had evidence of OS benefit >4 months in WHO-TRS and pivotal trials, respectively; 45.5% met ESMO-MCBS criteria. Ten targeted cancer drugs had more than one application for the same indications. Five of those were eventually recommended, including three without new evidence of OS benefit. Additional factors, such as reduced cost, and increased treatment options, seemed to be important factors in the selection. Conclusion While WHO has defined approval criteria for cancer drugs EML, we identified areas where adherence of these criteria and communication of the EML approval decision-making processes can be improved.

Item Type:	Article
Official URL:	https://gh.bmj.com/
Additional Information:	© 2023 The Author(s) (or their employer(s))
Divisions:	Health Policy
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Date Deposited:	07 Dec 2023 13:57
Last Modified:	03 Dec 2024 00:24
URI:	http://eprints.lse.ac.uk/id/eprint/121008

Actions (login required)

View Item